GlassScriptPhysician profile
Shenicka O'Brien
NPI 1215691217
$826.08
in general payments reported to CMS, 2019-2025
24 companies · $546 in 2025
The $546 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $148 · 2023: $88.18 · 2024: $43.84 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $104.10 | 2022-2024 | Dyanavel Xr |
| Novo Nordisk INC | $93.67 | 2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $64.52 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Ironshore Pharmaceuticals INC. | $56.88 | 2022-2023 | Jornay Pm |
| Exact Sciences Corporation | $55.79 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $44.71 | 2025 | Mounjaro, Zepbound |
| Sanofi Pasteur INC. | $36.98 | 2025 | |
| Aimmune Therapeutics, INC. | $31.89 | 2025 | Zenpep |
| Organon LLC | $28.82 | 2025 | Nexplanon |
| Corcept Therapeutics | $25.54 | 2025 | Korlym |
| Neurelis, INC. | $25.15 | 2024 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $25.00 | 2025 | Breztri |
| Pfizer INC. | $24.99 | 2025 | |
| Esperion Therapeutics, INC. | $23.49 | 2025 | Nexletol |
| Corium, LLC | $23.46 | 2023 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.35 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.34 | 2025 | |
| Phadia US INC. | $20.96 | 2025 | Immunocap |
| Gilead Sciences, INC. | $20.04 | 2025 | |
| Orexo US, INC. | $19.25 | 2025 | Zubsolv |
| Cranial Technologies, INC | $14.83 | 2023 | Doc Band |
| Seqirus USA INC | $14.31 | 2022 | |
| Evoke Pharma, INC. | $14.08 | 2025 | |
| Resmed Corp | $13.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shenicka O'Brien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.